Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 284.05
ABAX's Cash to Debt is ranked higher than
71% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. ABAX: 284.05 )
Ranked among companies with meaningful Cash to Debt only.
ABAX' s 10-Year Cash to Debt Range
Min: 0.46  Med: 172.39 Max: No Debt
Current: 284.05
Equity to Asset 0.86
ABAX's Equity to Asset is ranked higher than
87% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ABAX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
ABAX' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.86 Max: 0.9
Current: 0.86
0.48
0.9
F-Score: 6
Z-Score: 20.70
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.01
ABAX's Operating margin (%) is ranked higher than
89% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. ABAX: 18.01 )
Ranked among companies with meaningful Operating margin (%) only.
ABAX' s 10-Year Operating margin (%) Range
Min: -234.48  Med: 12.26 Max: 22.65
Current: 18.01
-234.48
22.65
Net-margin (%) 14.22
ABAX's Net-margin (%) is ranked higher than
90% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. ABAX: 14.22 )
Ranked among companies with meaningful Net-margin (%) only.
ABAX' s 10-Year Net-margin (%) Range
Min: -213.79  Med: 8.78 Max: 51.27
Current: 14.22
-213.79
51.27
ROE (%) 14.07
ABAX's ROE (%) is ranked higher than
81% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. ABAX: 14.07 )
Ranked among companies with meaningful ROE (%) only.
ABAX' s 10-Year ROE (%) Range
Min: -61.71  Med: 8.35 Max: 61.46
Current: 14.07
-61.71
61.46
ROA (%) 11.95
ABAX's ROA (%) is ranked higher than
89% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. ABAX: 11.95 )
Ranked among companies with meaningful ROA (%) only.
ABAX' s 10-Year ROA (%) Range
Min: -49.56  Med: 7.30 Max: 50.99
Current: 11.95
-49.56
50.99
ROC (Joel Greenblatt) (%) 52.25
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. ABAX: 52.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -331.01  Med: 31.27 Max: 57.43
Current: 52.25
-331.01
57.43
Revenue Growth (3Y)(%) 8.40
ABAX's Revenue Growth (3Y)(%) is ranked higher than
64% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ABAX: 8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.6  Med: 13.80 Max: 48.4
Current: 8.4
6.6
48.4
EBITDA Growth (3Y)(%) 19.90
ABAX's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ABAX: 19.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.9  Med: 21.80 Max: 171.4
Current: 19.9
-27.9
171.4
EPS Growth (3Y)(%) 16.20
ABAX's EPS Growth (3Y)(%) is ranked higher than
79% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ABAX: 16.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.2  Med: 6.30 Max: 159.6
Current: 16.2
-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ABAX Guru Trades in Q3 2014

Columbia Wanger 602,000 sh (New)
Jim Simons 7,600 sh (New)
PRIMECAP Management 1,973,200 sh (-0.13%)
Joel Greenblatt 16,012 sh (-39.12%)
» More
Q4 2014

ABAX Guru Trades in Q4 2014

Paul Tudor Jones 4,900 sh (New)
Joel Greenblatt 124,964 sh (+680.44%)
Jim Simons 34,000 sh (+347.37%)
Columbia Wanger 892,800 sh (+48.31%)
PRIMECAP Management 2,022,200 sh (+2.48%)
» More
Q1 2015

ABAX Guru Trades in Q1 2015

Jim Simons Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 2,021,200 sh (-0.05%)
Columbia Wanger 735,800 sh (-17.59%)
Joel Greenblatt 29,776 sh (-76.17%)
» More
Q2 2015

ABAX Guru Trades in Q2 2015

Steven Cohen 2,800 sh (New)
Paul Tudor Jones 7,880 sh (New)
Jim Simons 4,500 sh (New)
Joel Greenblatt 156,809 sh (+426.63%)
PRIMECAP Management 2,345,000 sh (+16.02%)
PRIMECAP Management 2,345,000 sh (+16.02%)
Columbia Wanger 848,025 sh (+15.25%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 36.14
ABAX's P/E(ttm) is ranked lower than
58% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. ABAX: 36.14 )
Ranked among companies with meaningful P/E(ttm) only.
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19  Med: 45.12 Max: 75.93
Current: 36.14
10.19
75.93
Forward P/E 38.17
ABAX's Forward P/E is ranked lower than
81% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. ABAX: 38.17 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 36.80
ABAX's PE(NRI) is ranked lower than
60% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. ABAX: 36.80 )
Ranked among companies with meaningful PE(NRI) only.
ABAX' s 10-Year PE(NRI) Range
Min: 10.15  Med: 44.89 Max: 74.58
Current: 36.8
10.15
74.58
P/B 4.74
ABAX's P/B is ranked lower than
67% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. ABAX: 4.74 )
Ranked among companies with meaningful P/B only.
ABAX' s 10-Year P/B Range
Min: 2.19  Med: 4.56 Max: 8.06
Current: 4.74
2.19
8.06
P/S 5.15
ABAX's P/S is ranked lower than
69% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. ABAX: 5.15 )
Ranked among companies with meaningful P/S only.
ABAX' s 10-Year P/S Range
Min: 2.48  Med: 5.02 Max: 8.54
Current: 5.15
2.48
8.54
PFCF 47.02
ABAX's PFCF is ranked lower than
63% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. ABAX: 47.02 )
Ranked among companies with meaningful PFCF only.
ABAX' s 10-Year PFCF Range
Min: 21.92  Med: 47.39 Max: 101.52
Current: 47.02
21.92
101.52
POCF 38.87
ABAX's POCF is ranked lower than
76% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. ABAX: 38.87 )
Ranked among companies with meaningful POCF only.
ABAX' s 10-Year POCF Range
Min: 17.34  Med: 33.92 Max: 77.91
Current: 38.87
17.34
77.91
EV-to-EBIT 25.09
ABAX's EV-to-EBIT is ranked lower than
62% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. ABAX: 25.09 )
Ranked among companies with meaningful EV-to-EBIT only.
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6  Med: 29.10 Max: 51.8
Current: 25.09
10.6
51.8
PEG 3.64
ABAX's PEG is ranked lower than
56% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. ABAX: 3.64 )
Ranked among companies with meaningful PEG only.
ABAX' s 10-Year PEG Range
Min: 0.19  Med: 2.02 Max: 13.47
Current: 3.64
0.19
13.47
Shiller P/E 54.24
ABAX's Shiller P/E is ranked lower than
78% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. ABAX: 54.24 )
Ranked among companies with meaningful Shiller P/E only.
ABAX' s 10-Year Shiller P/E Range
Min: 20.75  Med: 54.52 Max: 125.58
Current: 54.24
20.75
125.58
Current Ratio 7.03
ABAX's Current Ratio is ranked higher than
84% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. ABAX: 7.03 )
Ranked among companies with meaningful Current Ratio only.
ABAX' s 10-Year Current Ratio Range
Min: 1.54  Med: 5.78 Max: 9.82
Current: 7.03
1.54
9.82
Quick Ratio 5.84
ABAX's Quick Ratio is ranked higher than
81% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ABAX: 5.84 )
Ranked among companies with meaningful Quick Ratio only.
ABAX' s 10-Year Quick Ratio Range
Min: 1.12  Med: 4.75 Max: 8.45
Current: 5.84
1.12
8.45
Days Inventory 124.98
ABAX's Days Inventory is ranked lower than
72% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. ABAX: 124.98 )
Ranked among companies with meaningful Days Inventory only.
ABAX' s 10-Year Days Inventory Range
Min: 65.4  Med: 108.34 Max: 134.23
Current: 124.98
65.4
134.23
Days Sales Outstanding 51.27
ABAX's Days Sales Outstanding is ranked higher than
66% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. ABAX: 51.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABAX' s 10-Year Days Sales Outstanding Range
Min: 52.27  Med: 74.94 Max: 92.68
Current: 51.27
52.27
92.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.87
ABAX's Dividend Yield is ranked lower than
73% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. ABAX: 0.87 )
Ranked among companies with meaningful Dividend Yield only.
ABAX' s 10-Year Dividend Yield Range
Min: 0.21  Med: 0.50 Max: 0.87
Current: 0.87
0.21
0.87
Dividend Payout 0.41
ABAX's Dividend Payout is ranked lower than
62% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. ABAX: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
ABAX' s 10-Year Dividend Payout Range
Min: 0.2  Med: 0.39 Max: 0.48
Current: 0.41
0.2
0.48
Yield on cost (5-Year) 0.87
ABAX's Yield on cost (5-Year) is ranked lower than
72% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. ABAX: 0.87 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABAX' s 10-Year Yield on cost (5-Year) Range
Min: 0.21  Med: 0.50 Max: 0.86
Current: 0.87
0.21
0.86
Share Buyback Rate -0.50
ABAX's Share Buyback Rate is ranked higher than
74% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.70 vs. ABAX: -0.50 )
Ranked among companies with meaningful Share Buyback Rate only.
ABAX' s 10-Year Share Buyback Rate Range
Min: 0.4  Med: -2.30 Max: -12.4
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.44
ABAX's Price/Net Cash is ranked lower than
61% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. ABAX: 11.44 )
Ranked among companies with meaningful Price/Net Cash only.
ABAX' s 10-Year Price/Net Cash Range
Min: 5.92  Med: 15.32 Max: 300
Current: 11.44
5.92
300
Price/Net Current Asset Value 6.41
ABAX's Price/Net Current Asset Value is ranked higher than
57% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. ABAX: 6.41 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 3.41  Med: 7.29 Max: 41.88
Current: 6.41
3.41
41.88
Price/Tangible Book 4.77
ABAX's Price/Tangible Book is ranked higher than
52% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. ABAX: 4.77 )
Ranked among companies with meaningful Price/Tangible Book only.
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.88  Med: 5.05 Max: 36.9
Current: 4.77
2.88
36.9
Price/Projected FCF 2.41
ABAX's Price/Projected FCF is ranked lower than
62% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. ABAX: 2.41 )
Ranked among companies with meaningful Price/Projected FCF only.
ABAX' s 10-Year Price/Projected FCF Range
Min: 1.7  Med: 2.85 Max: 180.9
Current: 2.41
1.7
180.9
Price/DCF (Earnings Based) 2.16
ABAX's Price/DCF (Earnings Based) is ranked higher than
53% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. ABAX: 2.16 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.03
ABAX's Price/Median PS Value is ranked lower than
54% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. ABAX: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.31  Med: 0.95 Max: 8.88
Current: 1.03
0.31
8.88
Price/Peter Lynch Fair Value 2.62
ABAX's Price/Peter Lynch Fair Value is ranked lower than
62% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. ABAX: 2.62 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52  Med: 2.52 Max: 11.31
Current: 2.62
0.52
11.31
Price/Graham Number 3.13
ABAX's Price/Graham Number is ranked lower than
51% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. ABAX: 3.13 )
Ranked among companies with meaningful Price/Graham Number only.
ABAX' s 10-Year Price/Graham Number Range
Min: 1.42  Med: 3.02 Max: 10.96
Current: 3.13
1.42
10.96
Earnings Yield (Greenblatt) (%) 4.00
ABAX's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. ABAX: 4.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABAX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.9  Med: 3.40 Max: 9.5
Current: 4
1.9
9.5
Forward Rate of Return (Yacktman) (%) 15.76
ABAX's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. ABAX: 15.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABAX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 6.2  Med: 22.10 Max: 55.9
Current: 15.76
6.2
55.9

Analyst Estimate

Mar16 Mar17
Revenue(Mil) 215 240
EPS($) 1.26 1.36
EPS without NRI($) 1.26 1.36

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany,
Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market and point-of-care diagnostic instruments and consumables used in the veterinary market. The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Company's products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company's competitors in the point-of-care human medical diagnostic market are Inverness Medical Switzerland GmbH, now known as Alere Switzerland GmbH ("Alere"), Alfa Wassermann S.P.A., Johnson & Johnson, Ortho-Clinical Diagnostics, Inc. and F. Hoffmann-La Roche Ltd. The Company's Piccolo products are in vitro diagnostic medical devices subject to regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act (FDCA).
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
PRIMECAP Adds to Three Stakes in Portfolio Jul 07 2015 
Distribution: A Potentially Under-appreciated Moat Jun 08 2015 
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 
ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. Jan 13 2009 

More From Other Websites
ABAXIS INC Financials Aug 20 2015
10-Q for ABAXIS, Inc. Aug 12 2015
Strength Seen in ICU Medical (ICUI): Stock Soars 18.2% Aug 12 2015
BioScrip Loss Narrower than Expected, Strategic Plans in View - Analyst Blog Aug 11 2015
ABAXIS INC Files SEC form 10-Q, Quarterly Report Aug 10 2015
Abaxis, Inc. to Present at the Canaccord Genuity 35th Annual Growth Conference Aug 05 2015
Zimmer Biomet Tops Earnings, Guides Up; Awaits Synergy - Analyst Blog Jul 30 2015
Abaxis (ABAX) Tops Q1 Earnings on Strong Revenues, Margins - Analyst Blog Jul 24 2015
Why Abaxis, Inc. (ABAX) Could Be an Impressive Growth Stock - Tale of the Tape Jul 24 2015
Edited Transcript of ABAX earnings conference call or presentation 23-Jul-15 8:15pm GMT Jul 24 2015
Abaxis tops 1Q profit forecasts Jul 23 2015
Abaxis tops 1Q profit forecasts Jul 23 2015
ABAXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jul 23 2015
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2016, Declares Quarterly Cash... Jul 23 2015
Q1 2016 Abaxis Inc Earnings Release - After Market Close Jul 23 2015
5 Hated Earnings Stocks You Should Love Jul 21 2015
Abaxis (ABAX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape Jul 16 2015
Abaxis To Report First Quarter Fiscal Year 2016 Financial Results Thursday, July 23, 2015 Jul 16 2015
ABAXIS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Jul 10 2015
PRIMECAP Adds to Three Stakes in Portfolio Jul 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK